|MDACC Study No:||2012-0437 (clinicaltrials.gov NCT No: NCT01667419)|
|Title:||A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Vemurafenib (RO5185426) Adjuvant Therapy in Patients with Surgically Resected, Cutaneous BRAF-Mutant Melanoma at High Risk for Recurrence|
|Principal Investigator:||Kevin B. Kim|
|Study Description:||The goal of this clinical research study is to learn if vemurafenib is |
effective in preventing melanoma from coming back in patients who have the BRAF
mutation. The safety of vemurafenib will also be studied.
In this study, some patients will receive vemurafenib and some patients will
receive a placebo.
Vemurafenib is designed to block the BRAF gene mutation. This mutation causes
cancer and cancer growth. By blocking this mutation, the drug may kill the
cancer cells with the mutation and/or stop the tumor from growing.
A placebo is not a drug. It looks like the study drug but is not designed to
treat any disease or illness. It is designed to be compared with a study drug
to learn if the study drug has any real effect.